| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
320,801 |
421,551 |
1,262,027 |
1,480,093 |
| Total Sell Value |
$21,062,080 |
$26,516,522 |
$74,515,877 |
$82,888,946 |
| Total People Sold |
9 |
9 |
12 |
12 |
| Total Sell Transactions |
28 |
40 |
87 |
90 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carey Stephen P. |
SENIOR VICE PRESIDENT AND CFO |
• – – |
2022-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
33,875 |
142,208 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2022-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
19,934 |
131,803 |
|
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2022-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
19,428 |
34,378 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2022-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
100,055 |
252,251 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2022-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
19,428 |
31,168 |
|
- |
|
| Carey Stephen P. |
SENIOR VICE PRESIDENT AND CFO |
• – – |
2022-03-23 |
4 |
D |
$27.03 |
$112,634 |
D/D |
(4,167) |
108,333 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2022-03-23 |
4 |
D |
$27.03 |
$471,782 |
D/D |
(17,454) |
152,196 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2022-03-23 |
4 |
D |
$27.03 |
$66,278 |
D/D |
(2,452) |
111,869 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2022-03-21 |
4 |
B |
$27.69 |
$199,997 |
D/D |
7,224 |
169,650 |
0.01 |
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2022-03-21 |
4 |
B |
$27.87 |
$139,343 |
I/I |
5,000 |
393,226 |
0.01 |
- |
|
| Walsh Patrick D |
|
– • – |
2022-03-21 |
4 |
B |
$27.76 |
$138,794 |
D/D |
5,000 |
53,388 |
0.01 |
- |
|
| Tannenbaum Renee P |
|
– • – |
2022-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
13,346 |
13,346 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2022-03-18 |
4 |
B |
$27.15 |
$135,744 |
I/I |
5,000 |
388,226 |
0.01 |
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2022-03-17 |
4 |
B |
$27.65 |
$138,252 |
I/I |
5,000 |
5,000 |
0.01 |
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2022-03-17 |
4 |
B |
$27.65 |
$138,252 |
D/D |
5,000 |
18,460 |
0.01 |
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2022-02-15 |
4 |
D |
$40.25 |
$47,656 |
D/D |
(1,184) |
14,950 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2022-02-15 |
4 |
D |
$40.25 |
$46,972 |
D/D |
(1,167) |
11,740 |
|
- |
|
| Thoma Jeanne |
|
– • – |
2021-12-20 |
4 |
B |
$46.47 |
$49,820 |
D/D |
1,072 |
17,785 |
0.01 |
- |
|
| Pera Antonio R |
|
– • – |
2021-12-07 |
4 |
B |
$42.26 |
$126,794 |
D/D |
3,000 |
19,713 |
0.01 |
- |
|
| Haughey Thomas |
|
– • – |
2021-12-06 |
4 |
B |
$39.38 |
$98,450 |
D/D |
2,500 |
30,202 |
0.01 |
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2021-11-19 |
4 |
A |
$0.00 |
$0 |
I/I |
383,226 |
383,226 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2021-09-08 |
4 |
D |
$28.20 |
$72,671 |
D/D |
(2,577) |
162,426 |
|
- |
|
| Carey Stephen P. |
SENIOR VICE PRESIDENT AND CFO |
• – – |
2021-04-12 |
4 |
D |
$31.86 |
$96,918 |
D/D |
(3,042) |
112,500 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2021-04-12 |
4 |
D |
$31.86 |
$59,833 |
D/D |
(1,878) |
114,321 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2021-04-06 |
4 |
D |
$33.69 |
$11,354 |
D/D |
(337) |
116,199 |
|
- |
|
719 Records found
|
|
Page 8 of 29 |
|
|
0.14 (0.21%) 
